title: Ischemic brain cell-derived conditioned medium protects astrocytes against ischemia through GDNF/ERK/NF-kB signaling pathway.
abstract: Conditioned medium (CM) collected from cultures of ischemic microglia, astrocytes, and neurons were protective to astrocytes under the in vitro ischemic condition (deprivation of oxygen, glucose and serum). Molecular and signaling pathway(s) responsible for the CMs protective activity were investigated. Results showed that CMs from the ischemic microglia (MCM), astrocytes (ACM) and neurons (NCM) contained glial cell line-derived neurotrophic factor (GDNF), which protects astrocytes against the in vitro ischemia. Expression of extra cellular signal-regulated kinase (ERK1/2) and nuclear factor-kappa B (NF-kB) by GDNF led to the inhibition of apoptosis of the ischemic astrocytes in a caspase 3-independent manner. However, CMs- and GDNF-mediated protection of the ischemic astrocytes was protein kinase B (Akt) independent. These results provided mechanistic data regarding how GDNF- and CMs-mediated protection of the ischemic astrocytes is taking place. These observations provide information for the use of GDNF and GDNF containing CMs in the control of cerebral ischemia.
authors.affiliation: Department of Life Sciences, National Chung Hsing University, Taichung 40227, Taiwan.
authors.forename: Lan-Feng
authors.initials: LF
authors.lastname: Chu
authors.forename: Wei-Ti
authors.initials: WT
authors.lastname: Wang
authors.forename: Vithal K
authors.initials: VK
authors.lastname: Ghanta
authors.forename: Chi-Hsin
authors.initials: CH
authors.lastname: Lin
authors.forename: Yung-Yen
authors.initials: YY
authors.lastname: Chiang
authors.forename: Chi-Mei
authors.initials: CM
authors.lastname: Hsueh
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D001253:Astrocytes / Q000187:drug effects / Q000502:physiology*; D002545:Brain Ischemia / Q000378:metabolism*; D053148:Caspase 3 / Q000378:metabolism; D002478:Cells, Cultured; D017077:Culture Media, Conditioned; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism*; D051100:Glial Cell Line-Derived Neurotrophic Factor / Q000378:metabolism* / Q000494:pharmacology; D007511:Ischemia / Q000188:drug therapy / Q000503:physiopathology*; D017628:Microglia / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction
chemical_list: D017077:Culture Media, Conditioned; D051100:Glial Cell Line-Derived Neurotrophic Factor; D016328:NF-kappa B; D018696:Neuroprotective Agents; D051057:Proto-Oncogene Proteins c-akt; D048049:Extracellular Signal-Regulated MAP Kinases; D048052:Mitogen-Activated Protein Kinase 3; C505410:Casp3 protein, rat; D053148:Caspase 3